CJC-1295 and Ipamorelin, Explained

Researching CJC-1295 without DAC paired with ipamorelin for body recomposition, then asking what dose to start with, is one of the most common threads in peptide communities such as r/peptides^[7]. It is really two questions bundled into one: what do these two molecules do, and is there a dose that is safe and effective to start with. We can answer the first question honestly. The second one, a specific starting dose for a specific person's goals, is not something a general-audience article can responsibly answer. Here is why, and what a better next step looks like.

What CJC-1295 and ipamorelin actually do

CJC-1295 is a modified growth-hormone-releasing hormone (GHRH) analogue. It is built on the same amino-acid segment of GHRH that underlies tesamorelin, the peptide the FDA has approved as Egrifta for HIV-associated lipodystrophy. Ipamorelin works differently. It is a synthetic ghrelin mimetic that binds the GHS-R receptor on the pituitary gland and triggers a pulse of growth-hormone release. The two are commonly paired because they act on separate receptors that both drive the same pituitary output, one on the GHRH side and one on the ghrelin side of the axis. Cardiologist Eric Topol's July 2025 review of the peptide market describes the pairing this way, and also groups both peptides, along with tesamorelin, as carrying a theoretical, mechanism-based cancer-risk concern that the current evidence cannot rule in or out^[6].

The 'no DAC' detail that changes everything

The peptide most people actually buy online as CJC-1295 is not the molecule used in the original human studies. The original compound, CJC-1295 with DAC, carries a chemical linker that binds circulating albumin and stretches its half-life to roughly six to eight days. The 2006 study that established this, in healthy adults dosed at 30 to 60 micrograms per kilogram, reported no serious adverse reactions and described the with-DAC compound as safe and relatively well tolerated over that short observation window^[1]. CJC-1295 without DAC is a different molecule: the same GHRH backbone minus the albumin-binding linker, with a half-life closer to thirty minutes. Vendors routinely sell the without-DAC version under the plain CJC-1295 name, which means the pharmacokinetics a buyer expects from the published research and the pharmacokinetics of the vial they receive are often not the same thing.

Why there is no responsible starting dose to give you

The 2006 study on CJC-1295 with DAC covered a small group of healthy adults over a period of weeks, not months or years, and it was never followed by a completed phase-2 or phase-3 efficacy trial for any indication^[1]. Ipamorelin's human data has the same shape: short pharmacokinetic studies from the late 1990s and early 2000s, no completed efficacy trial, and no dose-response range established for body recomposition or any other goal. Neither peptide has a labelled human dose because neither has a label. Any number circulating in a forum thread, including doses framed as a beginner protocol, is an extrapolation from animal work, from the original pharmacokinetic studies, or from other users' self-reports, not from a trial designed to find a safe and effective human dose for your situation. A clinician who knows your bloodwork, training history and goals is the only person positioned to weigh that against your own risk profile, and even then the honest starting point is that the supporting evidence is thin.

Regulatory status: not approved anywhere, banned in sport

Neither peptide has a marketing authorisation in the United States, the EU, the UK, or any other jurisdiction PeptideMethods tracks. A DailyMed search for CJC-1295 returns a single listing, and it is a bulk ingredient for veterinary compounding, not a human medicine^[3]. A DailyMed search for ipamorelin returns no results at all^[4]. In the United States, the FDA's Pharmacy Compounding Advisory Committee reviewed ipamorelin's eligibility as a bulk substance for human compounding at its October 2024 meeting and did not add it to the approved list^[5]. Both peptides also sit on the World Anti-Doping Agency's Prohibited List under section S2, which covers GHRH analogues and growth-hormone secretagogues and bans them in and out of competition for any athlete subject to the WADA Code^[2]. That status is worth knowing even for someone training recreationally, since it signals how far these compounds sit from anything a regulator has reviewed for safety.

What we still don't know

The honest gap list is long. There is no published long-term human safety data for either peptide, so effects on glucose handling, fluid balance and IGF-1 levels over months or years are uncharacterised. There is no completed efficacy trial tying either peptide to body recomposition, sleep or recovery outcomes in humans. Grey-market supply chains rarely test for identity or purity, so a buyer often cannot confirm which molecule, or how much of it, is actually in the vial. And the cancer-risk question Topol raises is mechanistic, tied to sustained IGF-1 elevation as a class effect across growth-hormone-axis peptides, rather than grounded in a dedicated CJC-1295 or ipamorelin study^[6]. None of that is a reason for alarm on its own. It is a reason the honest answer to 'is this safe to start' is 'we do not have the data to tell you that.'

Where this leaves someone starting out

If body recomposition, meaning more lean mass and less fat at a similar bodyweight, is the actual goal, the levers with the strongest evidence base remain resistance training volume, protein intake, sleep and a sustained calorie approach matched to the goal. None of those carry the regulatory or safety uncertainty attached to CJC-1295 or ipamorelin. If a growth-hormone-axis peptide is still something worth exploring, that conversation belongs with a clinician or sports-medicine physician who can review your bloodwork and history, not a forum thread. Our peptide pages carry the full evidence and regulatory picture referenced here, including the with-DAC and without-DAC distinction, and are a reasonable stop before that conversation.